Literature DB >> 20147404

Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.

Jean-Philippe Julien1, Nerea Huarte, Rubén Maeso, Stefka G Taneva, Annie Cunningham, José L Nieva, Emil F Pai.   

Abstract

The identification and characterization of broadly neutralizing antibodies (bnAbs) against HIV-1 has formed a major research focus, with the ultimate goal to help in the design of an effective AIDS vaccine. One of these bnAbs, 2F5, has been extensively characterized, and residues at the apex of its unusually long complementarity-determining region (CDR) H3 loop have been shown to be crucial for neutralization. Structural studies, however, have revealed that the (100)TLFGVPI(100F) apex residues of the CDR H3 loop do not interact directly with residues of its core gp41 epitope. In an attempt to gain better insight into the functional role of this element, we have recombinantly expressed native 2F5 Fab and two mutants in which either the apical Phe100B(H) residue was changed to an alanine or the CDR H3 residues (100)TLFGVPI(100F) were replaced by a Ser-Gly dipeptide linker. Isothermal titration calorimetry (ITC) and competitive-binding enzyme-linked immunosorbent assays (ELISAs) rendered strikingly similar affinity constants (K(d) [dissociation constant] of approximately 20 nM) for linear peptide epitope binding by 2F5 Fabs, independent of the presence or absence of the apex residues. Ablation of the CDR H3 apex residues, however, abolished the cell-cell fusion inhibition and pseudovirus neutralization capacities of 2F5 Fab. We report competitive ELISA data that suggest a role of 2F5 CDR H3 apex residues in mediating weak hydrophobic interactions with residues located at the C terminus of the gp41 membrane proximal external region and/or membrane components in the context of core epitope binding. The present data therefore imply an extended 2F5 paratope that includes weak secondary interactions that are crucial for neutralization of Env-mediated fusion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20147404      PMCID: PMC2863773          DOI: 10.1128/JVI.02357-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

1.  A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies.

Authors:  Gary Frey; Hanqin Peng; Sophia Rits-Volloch; Marco Morelli; Yifan Cheng; Bing Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-05       Impact factor: 11.205

2.  Specificity in transmembrane helix-helix interactions mediated by aromatic residues.

Authors:  Neta Sal-Man; Doron Gerber; Itai Bloch; Yechiel Shai
Journal:  J Biol Chem       Date:  2007-05-08       Impact factor: 5.157

3.  Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.

Authors:  Jean-Philippe Julien; Steve Bryson; Jose L Nieva; Emil F Pai
Journal:  J Mol Biol       Date:  2008-09-18       Impact factor: 5.469

4.  Germline V-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus.

Authors:  Christy A Thomson; Steve Bryson; Gary R McLean; A Louise Creagh; Emil F Pai; John W Schrader
Journal:  EMBO J       Date:  2008-09-04       Impact factor: 11.598

Review 5.  Vaccines: correlates of vaccine-induced immunity.

Authors:  Stanley A Plotkin
Journal:  Clin Infect Dis       Date:  2008-08-01       Impact factor: 9.079

6.  Protective immunity following vaccination: how is it defined?

Authors:  Ian J Amanna; Ilhem Messaoudi; Mark K Slifka
Journal:  Hum Vaccin       Date:  2008-02-19

7.  An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.

Authors:  Josh D Nelson; Florence M Brunel; Richard Jensen; Emma T Crooks; Rosa M F Cardoso; Meng Wang; Ann Hessell; Ian A Wilson; James M Binley; Philip E Dawson; Dennis R Burton; Michael B Zwick
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

8.  Production of large unilamellar vesicles by a rapid extrusion procedure: characterization of size distribution, trapped volume and ability to maintain a membrane potential.

Authors:  M J Hope; M B Bally; G Webb; P R Cullis
Journal:  Biochim Biophys Acta       Date:  1985-01-10

9.  The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5.

Authors:  Nerea Huarte; Maier Lorizate; Rubén Maeso; Renate Kunert; Rocio Arranz; José M Valpuesta; José L Nieva
Journal:  J Virol       Date:  2008-07-02       Impact factor: 5.103

10.  Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Rachel M Klein; Maura M Manion; Sijy O'Dell; Adhuna Phogat; Bimal Chakrabarti; Claire W Hallahan; Stephen A Migueles; Jens Wrammert; Rafi Ahmed; Martha Nason; Richard T Wyatt; John R Mascola; Mark Connors
Journal:  J Virol       Date:  2008-10-15       Impact factor: 5.103

View more
  46 in total

1.  Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.

Authors:  Marit Kramski; Rob J Center; Adam K Wheatley; Jonathan C Jacobson; Marina R Alexander; Grant Rawlin; Damian F J Purcell
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Authors:  Marie Pancera; Jason S McLellan; Xueling Wu; Jiang Zhu; Anita Changela; Stephen D Schmidt; Yongping Yang; Tongqing Zhou; Sanjay Phogat; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

3.  Enhanced HIV-1 neutralization by antibody heteroligation.

Authors:  Hugo Mouquet; Malte Warncke; Johannes F Scheid; Michael S Seaman; Michel C Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-04       Impact factor: 11.205

Review 4.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

Authors:  Peter D Kwong; John R Mascola; Gary J Nabel
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

Review 5.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

6.  Scaffolding to build a rational vaccine design strategy.

Authors:  Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

7.  Elicitation of structure-specific antibodies by epitope scaffolds.

Authors:  Gilad Ofek; F Javier Guenaga; William R Schief; Jeff Skinner; David Baker; Richard Wyatt; Peter D Kwong
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-27       Impact factor: 11.205

8.  Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization.

Authors:  Mikyung Kim; Zhen-Yu J Sun; Kasper D Rand; Xiaomeng Shi; Likai Song; Yuxing Cheng; Amr F Fahmy; Shreoshi Majumdar; Gilad Ofek; Yongping Yang; Peter D Kwong; Jia-Huai Wang; John R Engen; Gerhard Wagner; Ellis L Reinherz
Journal:  Nat Struct Mol Biol       Date:  2011-10-16       Impact factor: 15.369

9.  Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6.

Authors:  Gilad Ofek; Brett Zirkle; Yongping Yang; Zhongyu Zhu; Krisha McKee; Baoshan Zhang; Gwo-Yu Chuang; Ivelin S Georgiev; Sijy O'Dell; Nicole Doria-Rose; John R Mascola; Dimiter S Dimitrov; Peter D Kwong
Journal:  J Virol       Date:  2013-12-11       Impact factor: 5.103

10.  Thermodynamic analysis of the binding of 2F5 (Fab and immunoglobulin G forms) to its gp41 epitope reveals a strong influence of the immunoglobulin Fc region on affinity.

Authors:  Sara Crespillo; Salvador Casares; Pedro L Mateo; Francisco Conejero-Lara
Journal:  J Biol Chem       Date:  2013-12-03       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.